Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma

NCT00436852 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT00436852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00436852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2007
Completion date
March 30, 2015
Enrollment
92 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

disseminated neuroblastoma, recurrent neuroblastoma